Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon.
[Diagnosis of multiple sclerosis - the 2010 revision of the McDonald criteria.]
ONO-4641 Met Primary Endpoint of Phase II Study in Multiple Sclerosis Patients
High dose thiamine improves fatigue in multiple sclerosis.
UVB light attenuates the systemic immune response in CNS autoimmunity.
Sanofi sees US FDA ruling for MS drug Lemtrada in Q4
Recurrence of disease activity after repeated Natalizumab withdrawals.
Topical Application of Fingolimod Perturbs Cutaneous Inflammation.
Recombinant T Cell Receptor Ligands Improve Outcome After Experimental Cerebral Ischemia.
Laminin-411 Is a Vascular Ligand for MCAM and Facilitates TH17 Cell Entry into the CNS.
Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis.
Guidelines for the use of intravenous immunoglobulin in the treatment of neurologic diseases.
Study Suggests Targeting B Cells May Help with MS
Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?
Medical marijuana: clearing away the smoke.
Managing fatigue in patients with multiple sclerosis.
Regression-Based Norms Improve the Sensitivity of the National MS Society Consensus Neuropsychological Battery for Pediatric Multiple Sclerosis (NBPMS).
The influence of ethnicity on the characteristics of multiple sclerosis: A local population study between Persians and Arabs.
Amiloride HCI Tablets, USP 5 mg
Teva Announces Approval of Three-Times-A-Week COPAXONE® 40 mg/mL in Russia for the Treatment of Relapsing-Remitting Multiple Sclerosis
Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study.
Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis.
Immunology 2012
A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis.
Effects of dalfampridine on multi-dimensional aspects of gait and dexterity in multiple sclerosis among timed walk responders and non-responders.

Pages